- Home
- PVL vs BLRX Comparison
PVL vs BLRX Comparison
Compare PVL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | BLRX |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 12.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | PVL | BLRX |
|---|---|---|
| Price | $1.83 | $2.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 51.1K | 26.7K |
| Earning Date | 03-20-2026 | 11-24-2025 |
| Dividend Yield | ★ 15.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $3,511,891.00 | ★ $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.57 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $1.30 | $2.30 |
| 52 Week High | $2.04 | $14.70 |
Technical Indicators
Market Signals| Indicator | PVL | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 41.52 |
| Support Level | $1.77 | $2.81 |
| Resistance Level | $1.84 | $3.10 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 83.33 | 29.23 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.